These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 16283417)

  • 1. Successful treatment of a patient with primary Sjögren's syndrome with Rituximab.
    Ring T; Kallenbach M; Praetorius J; Nielsen S; Melgaard B
    Clin Rheumatol; 2006 Nov; 25(6):891-4. PubMed ID: 16283417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distal renal tubular acidosis associated with Sjögren's syndrome.
    Yasuda K; Sasaki K; Yamato M; Hayashi T
    Intern Med; 2012; 51(6):675-6. PubMed ID: 22449687
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjögren's syndrome.
    Pijpe J; Meijer JM; Bootsma H; van der Wal JE; Spijkervet FK; Kallenberg CG; Vissink A; Ihrler S
    Arthritis Rheum; 2009 Nov; 60(11):3251-6. PubMed ID: 19877054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome.
    Pers JO; Devauchelle V; Daridon C; Bendaoud B; Le Berre R; Bordron A; Hutin P; Renaudineau Y; Dueymes M; Loisel S; Berthou C; Saraux A; Youinou P
    Arthritis Rheum; 2007 May; 56(5):1464-77. PubMed ID: 17469105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab therapy in primary Sjögren's syndrome.
    Alcântara C; Gomes MJ; Ferreira C
    Ann N Y Acad Sci; 2009 Sep; 1173():701-5. PubMed ID: 19758218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetes mellitus and renal tubular acidosis in primary Sjögren's syndrome.
    Prakash EB; Jayanth JJ; Fernando ME
    J Assoc Physicians India; 2010 Jul; 58():451-3. PubMed ID: 21121214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with infliximab restores normal aquaporin 5 distribution in minor salivary glands of patients with Sjögren's syndrome.
    Steinfeld SD; Appelboom T; Delporte C
    Arthritis Rheum; 2002 Aug; 46(8):2249-51. PubMed ID: 12209534
    [No Abstract]   [Full Text] [Related]  

  • 8. Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjögren's syndrome.
    Cornec D; Costa S; Devauchelle-Pensec V; Jousse-Joulin S; Marcorelles P; Berthelot JM; Chiche L; Hachulla E; Hatron PY; Goeb V; Vittecoq O; Saraux A; Pers JO
    J Autoimmun; 2016 Feb; 67():102-110. PubMed ID: 26688003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence of focal lymphocytic sialadenitis in patients with primary Sjögren's syndrome treated with rituximab: a possible role for glandular BAFF.
    Carubbi F; Cipriani P; Di Benedetto P; Ruscitti P; Alunno A; Gerli R; Giacomelli R
    Clin Exp Rheumatol; 2016; 34(6):1123-1124. PubMed ID: 27494407
    [No Abstract]   [Full Text] [Related]  

  • 10. Successful treatment of renal tubular acidosis and recurrent secondary struvite kidney stones with rituximab in a patient with primary Sjögren's syndrome.
    Schilcher G; Schwarz C; Hermann J
    Rheumatology (Oxford); 2017 Mar; 56(3):498-500. PubMed ID: 28031439
    [No Abstract]   [Full Text] [Related]  

  • 11. B cell reconstitution and T helper cell balance after rituximab treatment of active primary Sjögren's syndrome: a double-blind, placebo-controlled study.
    Abdulahad WH; Meijer JM; Kroese FG; Meiners PM; Vissink A; Spijkervet FK; Kallenberg CG; Bootsma H
    Arthritis Rheum; 2011 Apr; 63(4):1116-23. PubMed ID: 21225693
    [No Abstract]   [Full Text] [Related]  

  • 12. First report of improvement of coeliac disease in a patient with Sjögren's syndrome treated with rituximab.
    Nikiphorou E; Hall FC
    Rheumatology (Oxford); 2014 Oct; 53(10):1906-7. PubMed ID: 24729401
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment approaches in primary Sjogren syndrome.
    Vissink A; Kallenberg CG; Bootsma H
    JAMA; 2010 Nov; 304(18):2015-6; author reply 2016. PubMed ID: 21063008
    [No Abstract]   [Full Text] [Related]  

  • 14. [B-cell depletion and primary Sjögren's syndrome: is there a role for rituximab?].
    Atzeni F; Sarzi-Puttini P
    Reumatismo; 2010; 62(2):87-8. PubMed ID: 20657883
    [No Abstract]   [Full Text] [Related]  

  • 15. Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjögren's syndrome after B cell depletion therapy.
    Hamza N; Bootsma H; Yuvaraj S; Spijkervet FK; Haacke EA; Pollard RP; Visser A; Vissink A; Kallenberg CG; Kroese FG; Bos NA
    Ann Rheum Dis; 2012 Nov; 71(11):1881-7. PubMed ID: 22615459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren's syndrome and associated MALT lymphoma.
    Pijpe J; van Imhoff GW; Vissink A; van der Wal JE; Kluin PM; Spijkervet FK; Kallenberg CG; Bootsma H
    Ann Rheum Dis; 2005 Jun; 64(6):958-60. PubMed ID: 15576414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential therapy with belimumab followed by rituximab in Sjögren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy.
    De Vita S; Quartuccio L; Salvin S; Picco L; Scott CA; Rupolo M; Fabris M
    Clin Exp Rheumatol; 2014; 32(4):490-4. PubMed ID: 24802131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histological improvement in salivary gland along with effector memory Th17-1 cell reduction in a primary Sjogren's syndrome patient with dermatomyositis and diffuse large B-cell lymphoma by R-CHOP therapy.
    Koga T; Mizokami A; Nakashima M; Shimizu T; Nakashima Y; Nakamura H; Chiwata M; Daisuke N; Kawakami A
    Clin Immunol; 2016 Apr; 165():35-7. PubMed ID: 26960952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20).
    Devauchelle-Pensec V; Pennec Y; Morvan J; Pers JO; Daridon C; Jousse-Joulin S; Roudaut A; Jamin C; Renaudineau Y; Roué IQ; Cochener B; Youinou P; Saraux A
    Arthritis Rheum; 2007 Mar; 57(2):310-7. PubMed ID: 17330280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab modulates IL-17 expression in the salivary glands of patients with primary Sjögren's syndrome.
    Ciccia F; Guggino G; Rizzo A; Alessandro R; Carubbi F; Giardina A; Cipriani P; Ferrante A; Cannizzaro A; Giacomelli R; Triolo G
    Rheumatology (Oxford); 2014 Jul; 53(7):1313-20. PubMed ID: 24602921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.